Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack
Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.
Nanopharm & FLUIDDA Interviews on SmartTrack: In Vitro-In Silico Approaches for Demonstrating Bioequivalence for OINDP
To support generic drug companies in obtaining a market license for their orally inhaled drug products (OIDPs), Nanopharm and FLUIDDA entered into an exclusive collaboration to combine Nanopharm’s SmartTrack™ with FLUIDDA’s Functional Respiratory Imaging technology to create a unique in-vitro in-silico platform. This allows pharma companies to shorten their clinical pathways – and potentially avoid […]
A Holistic Demonstration of SmartTrack™ and New Ways of Collaborating Combine for a Successful FDA Workshop
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Intranasal Drug Delivery: Unravelling the Nanoparticle Formulation Puzzle
Navigate the complexities of formulating nanoparticles for intranasal drug delivery with expert insights
Propellant Aerosols & Transition to Low GWP pMDIs
Understand how the properties of propellant aerosols guide the transition to low global warming potential pMDIs.
Albuterol & Low GWP Propellants: Deposition Prediction
Explore predictions of regional deposition and systemic exposure of Albuterol Sulfate with low global warming potential propellants in pMDIs.
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
Assessing Particle Size in DPIs with Spraytec & Unidose
Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.
Pulmonary Fate of Fluticasone: Challenges Met
Nanopharm investigate the pulmonary effect of Fluticasone and related compounds, addressing physiologic and pharmacokinetic challenges.
